StockCall.com Provides Stock Research on Gilead Sciences Inc., NPS Pharmaceuticals Inc., Halozyme Therapeutics Inc., Santarus Inc., and InterMune Inc.
New York City, New York -- (May 30, 2013)
The U.S. biotechnology sector is facing significant competition from generic drug makers. Competition from generic drug makers is expected to rise going forward as patents on several blockbuster drugs are set to expire. The key for biotechnology companies will be to increase their spending on research and development in order to boost their product pipelines. Biotech companies should also look at collaborating with big pharma companies as well as institutions to boost their product pipelines. Shares in biotechnology companies ended mostly lower on Wednesday, May 29, 2013, tracking losses in the broad market. The major movers in the sector includedGilead Sciences Inc. (NASDAQ: GILD), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), Halozyme Therapeutics Inc. (NASDAQ: HALO), Santarus Inc. (NASDAQ: SNTS) and InterMune Inc. (NASDAQ: ITMN). StockCall has posted free technicalresearch on GILD, NPSP, HALO, SNTS, and ITMN which can be downloaded upon sign up at
Shares in Gilead Sciences Inc. moved lower yesterday, tracking losses in the broader market. The stock hit an intraday high of $56.19, before finishing the day 0.98% lower at $55.63. So far this year, the share has grown more than 53%, outperforming the S&P 500. The company’s stock currently trades below both their 20- and 50-day moving average price of $54.63 and $51.36 respectively. Gilead’s shares saw volume turnover of 9.68 million during Wednesday’s trading session. Its beta of 0.52 implies low volatility.Sign up and read the complimentary report on GILD at
Shares in NPS Pharmaceuticals Inc. experienced a deep loss on Wednesday as its stock declined 4.43% to close at $15.09. A total of 1.83 million shares were traded during the session, while its average daily trading volume stands at 1.96 million. Additionally, the stock oscillated between $15.05 and $15.82. Over the past five trading days, the stock grew 0.13% while the markets wavered. So far this year, the share has increased 68.04%. NPS Pharmaceuticals’ shares have low volatility with beta of 0.62, and the company commands market capitalization of $1.51 billion. The free report on NPSP can be downloaded by signing up now at
Halozyme Therapeutics Inc.’s stock ended lower yesterday, down 2.42% at $7.25. A total of 966,862 shares were traded. With the wider market swaying sideways during the past five sessions, the company’s shares tumbled 8.92%. The stock has added 9.02% so far this year. During Wednesday session, the stock traded between $7.24 and $7.66 while its 52 weeks trading range stands at $3.86 and $9.92. Halozyme commands market capitalization of $820.41 million. Its stock is highly volatile as implied by its beta of 1.51. Free report on HALO can be accessed by registering at
Santarus Inc.’s stock hit an intraday low of $22.11 to finish the day 2.06% lower at $22.40. A total of 910,628 shares were traded in comparison to its usual trading volume of 1.52 million shares. The stock is up 108.37% so far this year. In the past 52 weeks, the stock traded between $4.82 and $24. Santarus shows high volatility as implied by its beta of 1.34. The stock is currently trading above its 20-day moving average price of $20.96 and 50-day moving average price of $19.07. SNTS commands market capitalization of $1.46 billion.Register withStockCall and download the research on SNTS for free at
InterMune Inc.’s stock ended higher on Wednesday, finishing 1.22% up at $9.98. A total of 1.15 million shares were traded during the session. The stock’s usual trading volume stands at 1.36 million shares. In the past 52 weeks, the stock traded between $7.21 and $12.77. InterMune commands market capitalization of $814.57 million, and its stock is currently trading below its short-term moving average price of $10.01. Read the full free research on ITMN by signing up to StockCall at
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
William T. Knight
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)
Leave a comment...